Key result
Newer self-expandable valves match balloon-expandable valves for primary efficacy in transfemoral TAVI.
Why the study?
Does a newer generation self-expandable valve compared to a balloon-expandable valve provide equivalent outcomes in patients with symptomatic aortic stenosis undergoing transfemoral TAVI?
RCT (n=447)
Open-label
2 × 2 factorial
Yes
Does a newer generation self-expandable valve compared to a balloon-expandable valve provide equivalent outcomes in patients with symptomatic aortic stenosis undergoing transfemoral TAVI?
Newer generation self-expandable and balloon-expandable valves demonstrate equivalent 30-day composite efficacy and safety outcomes in patients undergoing transfemoral TAVI.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“One of the things we've been wondering is whether these gradients, which are reliably lower with the self-expanding valve, translate into something clinically, whether it's differences in durability or whether it's differences in mortality, and you didn't see any mortality difference.”
“The fact that trials like these are being done is a testament to how far this technology has evolved. We're not asking the question anymore whether TAVR is valid or not, but rather which device, and that's a testament to all the work that's been done in the field.”
“in 90% of aortic stenosis cases, it doesn't matter which valve is used, and many institutions typically use one device over another. This is usually related more to operator experience or supplier relationships than clinical characteristics.”
Supports valve selection by operator expertise and anatomy in most TAVI cases; reinforces equivalence of newer-generation platforms.
AIMS: Transcatheter aortic valve implantation (TAVI) has emerged as established treatment option in patients with symptomatic aortic stenosis. Technical developments in valve design have addressed previous limitations such as suboptimal deployment, conduction disturbances, and paravalvular leakage. However, there are only limited data available for the comparison of newer generation self-expandable valve (SEV) and balloon-expandable valve (BEV). METHODS AND RESULTS: SOLVE-TAVI is a multicentre, open-label, 2 × 2 factorial, randomized trial of 447 patients with aortic stenosis undergoing transfemoral TAVI comparing SEV (Evolut R, Medtronic Inc., Minneapolis, MN, USA) with BEV (Sapien 3, Edwards Lifesciences, Irvine, CA, USA). The primary efficacy composite endpoint of all-cause mortality, stroke, moderate/severe prosthetic valve regurgitation, and permanent pacemaker implantation at 30 days was powered for equivalence (equivalence margin 10% with significance level 0.05). The primary composite endpoint occurred in 28.4% of SEV patients and 26.1% of BEV patients meeting the prespecified criteria of equivalence [rate difference -2.39 (90% confidence interval, CI -9.45 to 4.66); Pequivalence = 0.04]. Event rates for the individual components were as follows: all-cause mortality 3.2% vs. 2.3% [rate difference -0.93 (90% CI -4.78 to 2.92); Pequivalence < 0.001], stroke 0.5% vs. 4.7% [rate difference 4.20 (90% CI 0.12 to 8.27); Pequivalence = 0.003], moderate/severe paravalvular leak 3.4% vs. 1.5% [rate difference -1.89 (90% CI -5.86 to 2.08); Pequivalence = 0.0001], and permanent pacemaker implantation 23.0% vs. 19.2% [rate difference -3.85 (90% CI -10.41 to 2.72) in SEV vs. BEV patients; Pequivalence = 0.06]. CONCLUSION: In patients with aortic stenosis undergoing transfemoral TAVI, newer generation SEV and BEV are equivalent for the primary valve-related efficacy endpoint. These findings support the safe application of these newer generation percutaneous valves in the majority of patients with some specific preferences based on individual valve anatomy.
No takes yet. Share an insight, caveat, or question.
Thiele et al. (2020) conducted an RCT in Aortic stenosis (n=447). Self-expandable valve (Evolut R) vs. Balloon-expandable valve (Sapien 3) was evaluated on Composite endpoint of all-cause mortality, stroke, moderate/severe prosthetic valve regurgitation, and permanent pacemaker implantation at 30 days (rate difference -2.39, 95% CI -9.45 to 4.66, p=0.04 for equivalence). Self-expandable valves were equivalent to balloon-expandable valves for the 30-day primary composite efficacy endpoint.
Synapse has enriched 10 related papers. Consider them for comparative context: